TY - JOUR T1 - Hormone therapy for younger women may not increase CHD risk during 5–7 years follow-up, but stroke risk was increased independent of age JF - Evidence Based Medicine JO - Evid Based Med SP - 137 LP - 137 DO - 10.1136/ebm.12.5.137 VL - 12 IS - 5 A2 - , Y1 - 2007/10/01 UR - http://ebm.bmj.com/content/12/5/137.abstract N2 - Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77.OpenUrlCrossRefPubMedWeb of Science Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Gynaecology ★★★★★★★ Cardiology ★★★★★☆☆ IM/Ambulatory care ★★★★★☆☆ Design: 2 randomised placebo-controlled trials (Women’s Health Initiative [WHI] trials). Allocation: {concealed}*.† Blinding: blinded {clinicians, participants, data collectors, outcome assessors, and monitoring committee}*.† Follow-up period: mean 5.6‡ and 7.1§ years. Setting: 40 US clinical centres. Participants: 27 347 predominantly healthy postmenopausal women 50–79 years of age (mean age 63* and 64|| y). Intervention conjugated equine oestrogen (CEO), 0.625 mg/day, plus medroxyprogesterone acetate, 2.5 mg/day (n = 8506), or placebo (n = 8102) in women with an intact uterus; CEO, 0.625 mg/day (n = 5310), or placebo (n = 5429) in women with a hysterectomy. Outcomes: coronary heart disease (CHD) (myocardial infarction or CHD death), stroke, total mortality, and a global index. Participant follow-up: 94%‡|| (intention-to-treat analysis). Overall, the HT and placebo groups did not differ for CHD, total mortality, and the global index; the risk of stroke was higher in the HT group … ER -